Product Wiki · Recalls · EU Safety Gate (RAPEX)

Lightening body lotion — recall A12/02770/24

EU Safety Gate (RAPEX) · Germany · 2024-10-04 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/02770/24
Date of alert
2024-10-04
Country / jurisdiction
Germany
Risk level
Serious risk
Risk type
Chemical
Brand
White Secret
Product category
Cosmetics
Product type
Skin-lightening lotion
Barcode (EAN/GTIN)
6028050098819
Reported risk: Das Produkt enthält Hydrochinon (Messwert: 1,01 Gewichtsprozent), das in kosmetischen Produkten verboten ist. Hydrochinon kann allergische Kontaktdermatitis und schwere Augenschäden verursachen. Das Produkt entspricht nicht der Kosmetik-Verordnung.
Action taken by the authority
Type of economic operator taking notified measure
Retailer
Category of measure
Withdrawal of the product from the market
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): Lightening body lotion

Risk Description (original English): The product contains hydroquinone (measured value: 1.01% by weight) which is prohibited in cosmetic products. Hydroquinone can cause allergic contact dermatitis and serious eye damage.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10075846

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.